It reads like the agreement happened on September 15th.
Cut/Paste from three sections of the 8K follows.
"License And Distribution Agreement
This License and Distribution Agreement (this ?Agreement?) is made on September 15, 2022 (the ?Effective Date?) by and between Axim Biotechnologies, Inc. (?Licensor?), a Nevada corporation, and Vers?a Ophthalmics, LLC, a Delaware limited liability company (?Licensee?)."
"1.2. Term
This Agreement is effective upon the Effective Date. This Agreement will last for an initial term of five (5) years from the Effective Date (the ?Initial Term?). Thereafter, this Agreement will renew automatically for sequential two (2) year terms (each, a ?Renewal Term? and, together with the Initial Term, the ?Term?) unless either party, within ninety (90) days prior to the end of the Initial Term or the applicable Renewal Term, as the case may be, notifies the other party in writing of its intent to terminate this Agreement. During the Term, and for a one (1) year period thereafter, Licensee and its Sub-Distributors shall not sell, distribute, and /or market within the Territory any product testing for the same FDA 510k cleared analytes as the Products, including IgE, lactoferrin, or MMP-9."
"SCHEDULE B-1
Consideration
Rights for Lactoferrin and IgE Tests
Exclusive distribution rights with private label Vers?a branding.
Initial License Fee. $[ ]
Prepayment.
100% for initial 6 months order
1.The License Fee of $[ ] is payable within seventy-two (72) hours of execution of this Agreement.
Market Data 
Markets 
AI
